This study was conducted to determine whether Pneumocystis carinii dyhydropteroate synthase (DHPS) gene mutations in AIDS patients with P. carinii pneumonia (PCP) are affected by duration of sulfa or sulfone prophylaxis and influence response to sulfa or sulfone therapy. The P. carinii DHPS genes from 97 AIDS patients with PCP between 1991 and 1999 from 4 medical centers were amplified, using polymerase chain reaction (PCR), and sequenced. Mutations were observed in 76% of isolates from patients exposed to sulfa or sulfone prophylaxis compared with 23% of isolates from patients not exposed ( ). Duration of prophylaxis P p .001 increased the risk of mutations (relative risk [RR] for each exposure month, 1.06;
Pneumocystis carinii Mutations Are Associated with Duration of Sulfa or Sulfone Prophylaxis Exposure in AIDS Patients
in AIDS patients with PCP who were exposed to sulfa or sulfone prophylaxis [12] . Other groups [13] [14] [15] have subsequently confirmed this finding. Mutations in DHPS are critical, even though sulfamethoxazole is usually administered in combination with trimethoprim, a dihydrofolate reductase (DHFR) inhibitor. A recent study has shown that DHPS, but not DHFR, mutations are associated with prophylaxis exposure [15] .
Several questions concerning P. carinii DHPS, however, remain unanswered. For example, the contribution that duration and dose of a sulfa and sulfone have on the presence of DHPS mutations has not been determined. Also, it is unknown whether the incidence of DHPS mutations varies with geographic locale. Finally, although one report has demonstrated reduced 3-month survival in patients who harbor DHPS mutations [14] , the effect of DHPS mutations on response to sulfa or sulfone therapy has not been evaluated. We conducted this multicenter study, using a larger number of specimens obtained from 4 geographic locales, to investigate these questions further.
Materials and Methods
Patient specimens from Indiana University Medical Center (IUMC, Indianapolis), Wayne State University Medical Center (WSU, Detroit), Brigham and Women's Hospital (BWH, Boston), and Denver Health Medical Center (DHMC, Denver) were obtained for diagnostic purposes. Centers located in the eastern, midwestern, and western portions of the United States were chosen for this study in order to investigate variations in P. carinii DHPS mutations over the broadest geographic range possible. Preserved Downloaded from https://academic.oup.com/jid/article-abstract/182/2/551/2191531 by guest on 18 December 2018 alcohol-fixed slides, paraffin-embedded cytopathology tissue, or frozen samples were obtained from bronchoalveolar lavage or sputum induction specimens were delivered to the University of Michigan for PCR analysis. The investigational review board at each institution approved the study. The dose and duration of a sulfa-or sulfone-containing chemoprophylactic agent (i.e., dapsone or TMP/SMX) was abstracted from patient charts. Significant exposure to a sulfa-or sulfonecontaining agent was defined as the use of dapsone or TMP/SMX for у1 of the 4 months preceding the date of diagnosis of PCP. The agent or agents used to treat PCP at treatment initiation until completion of treatment were also ascertained from patient charts. In addition, clinical findings (presence of cough and dyspnea, temperature, respiratory rate, and pulmonary findings noted on physical examination) and laboratory results (arterial blood gas testing, PAO 2 and PaO 2 , and radiographic tests) were also abstracted from patient charts. All chart abstractions were performed without knowledge of the P. carinii DHPS PCR results.
Sulfa or sulfone therapy failure was classified by deterioration after 7 days of therapy, defined by worsening clinical features or gas exchange parameters (i.e., an increase in PAO 2 -PaO 2 by у20 mm Hg over the base-line value, when available). Change in sulfa or sulfone therapy because of physician's perception of failure, or failure of clinical findings to improve after 10 days of therapy, were also criteria used to define failure of sulfa or sulfone treatment. Changes in sulfa therapy that were made because of an adverse reaction were not considered sulfa failure. We used neither persistence of fever (because of its multifactorial nature) nor lack of improvement seen on chest radiograph (because of its typical lag behind clinical improvement and the potential for interobserver variation) to assess exclusively therapeutic failure. Patients were considered to have had successful response to sulfa or sulfone treatment if they met the following criteria: a sulfa or sulfone agent had been received for у7 days, the patient had improvement in all abnormal clinical findings and measures of gas exchange (when available), and the patient survived the episode. The same criteria used to judge sulfa or sulfone treatment response were used to evaluate response to nonsulfa and nonsulfone agents: pentamidine, primaquine plus clindamycin, trimetrexate, and atovaquone. Survival at 4 weeks of treatment was noted. All assessments of treatment failure were performed without knowledge of the P. carinii DHPS PCR results.
DNA was extracted from all samples and then amplified by PCR in a PTC-100 programmable thermal controller (MJ Research, Waterstown, MA), as described elsewhere [12] . If bands were present, the DNA was sequenced directly. Eighty samples were subsequently subjected to nested PCR as described elsewhere [12] .
Reaction products were purified on 1.2% low-melt agarose (Gibco BRL, Grand Island, NY), extracted with a Gel Extraction Kit (Qiagen, Chatsworth, CA), and sequenced on an Applied Biosystems Model 373a automated DNA sequencer using A NEST and B NEST as sequencing primers. DNA and amino acid sequences were aligned using MacVector version 5.0 (International Biotechnologies, New Haven, CT).
Statistics were performed using SPSS version 9.0. Binary logistic regression multivariate analysis was used to determine independent associations between sulfa and sulfone use, dose, duration of chemoprophylaxis, and geographic location with DHPS polymorphisms. Associations between DHPS polymorphisms and response to sulfa or sulfone treatment were performed using x 2 analysis. A P value !.05 was considered significant. The DNA extraction and PCR processing were performed in a blinded fashion, without knowledge of sulfa or sulfone prophylaxis or treatment information.
Results
One hundred thirty-five AIDS patients with PCP for whom stored respiratory specimens from January 1991 to April 1999 and complete medical records were available were identified. The DHPS gene was successfully PCR-amplified from the identified stored specimens in 97 patients; these patients were inDownloaded from https://academic.oup.com/jid/article-abstract/182/2/551/2191531 by guest on 18 December 2018 cluded in the study. There were no differences in the clinical characteristics between the 97 patients with PCP in this study and the 38 remaining patients for whom DNA could not be extracted from retrieved slides.
The demographic and clinical characteristics of the 97 patients with PCP, according to whether mutations were present or absent, are shown in table 1. The samples were obtained from AIDS patients between 1991 and 1999. These patients had a mean age of years (range, 25-61), a mean CD4 37 ‫ע‬ 51 count of (range, 9-210), and a mean human immuno-77 ‫ע‬ 63 deficiency virus (HIV) viral load of logs. Sixty-seven 4.3 ‫ע‬ 2.3 patients had ever received an antiretroviral agent; 76% of patients were homosexual men. Eight patients had a previous episode of PCP, and no patient had a previous episode of cerebral toxoplasmosis. There were no significant differences in any demographic or clinical characteristics between those who had and those who did not have P. carinii mutations. Four of the 60 patients who did not have significant sulfa or sulfone prophylaxis had received a sulfa or sulfone agent for other purposes for a duration of 7, 10, 14, and 18 days. None of the 4 patients was receiving sulfa or sulfone agents at the time of PCP onset.
Thirty-seven patients received prophylaxis with a sulfa agent (TMP/SMX, 9 patients) or a sulfone agent (dapsone, 28 patients), for a mean duration of months (range, 3-76 16.5 ‫ע‬ 9.7 months). The median duration of sulfa or sulfone prophylaxis was 11.4 months. Of the patients receiving dapsone, the doses were 100 mg daily (21 patients) and 50 mg daily (7 patients). Of the patients receiving TMP/SMX, the doses were 1 doublestrength (DS) tablet daily (6 patients), 1 single-strength (SS) tablet daily (2 patients), and 1 DS tablet 3 times weekly (1 patient). Thirty of the 37 patients taking sulfa or sulfone as prophylaxis were receiving dapsone or TMP/SMX at the time of the diagnosis of PCP; 6 patients discontinued TMP/SMX within 2 months of the episode of PCP because of intolerance, and 2 patients discontinued dapsone because of intolerance. Thus, 3 of the 9 patients with TMP/SMX prophylaxis exposure and 26 of the 28 patients with dapsone prophylaxis exposure were receiving these respective agents at the time of PCP occurrence. No patient had received or was receiving sulfadiazine as therapy for toxoplasmosis prior to the episode of PCP.
Seventy-eight samples were amplified by a single round of PCR. These yielded sequences that were 720-742 nucleotides long and were identical to previously published sequences [12] . Nineteen samples were amplified by nested PCR. For them, the sequences measured were 300-323 nucleotides long [12] . Forty-two samples contained either 1 or 2 nonsynonymous nucleotide changes identical to ones described elsewhere [12] . One sample contained mixtures of 2 nucleotides at both variable positions. Thus, 4 sequence patterns were found for the deduced amino acid sequences (table 2). The most common P. carinii DHPS sequence, seen in 57 patients, contained threonine at position 55 and proline at position 57. In one patient, the DHPS had a single change at position 57, with serine replacing proline. Forty additional patients had this change, as well as alanine instead of threonine at position 55. Finally, one patient had a mixture of both amino acids at both positions. The thr55/pro57 pattern was seen in most patients as well as in all samples taken from patients prior to 1993 (tables 2 and 3). Both of these amino acids are present in homologous DHPS genes from both murine and rat-derived P. carinii [12] . This is defined as the wild-type (WT) sequence, as in our previously published articles. DHPS sequences containing either 1 or 2 changes or a mixture of WT and altered sequences were considered to be mutants.
AIDS patients who had significant exposure to TMP/SMX or dapsone prophylaxis were more likely to yield mutant P. carinii DHPS sequences; this difference was statistically significant (RR, 2.5;
). Only 14 (23%) of 60 AIDS patients P p .001 who did not have significant exposure to prophylaxis with a sulfa-or sulfone-containing agent had mutant DHPS genes (table 4). In contrast, 28 (76%) of 37 AIDS patients who had significant exposure to sulfa or sulfone prophylaxis demonstrated mutant DHPS genes. Mutations were present in 2 of the 4 patients who had not received significant sulfa or sulfone prophylaxis but had received a sulfa or sulfone agent for other purposes. All of the 42 mutant isolates came from the 80 patient samples obtained in 1993-1999; there were no mutations seen in the 17 isolates from 1991-1992 (table 3) . This suggests that mutant strains have begun to appear recently. The percentage of all patients with mutations varied according to geographic locale: it ranged from 24% (Indianapolis) to 75% (Detroit). For patients who did not receive sulfa or sulfone prophylaxis, the percentage of mutations ranged from 14% (Indianapolis) to 71% (Detroit) (table 4) . There was a significant association between the duration of sulfa or sulfone prophylaxis and the risk of having a DHPS mutation (table 5) . For each month of sulfa exposure, there was a statistically significant increase in harboring a DHPS mutation (RR, 1.06; ). Similarly, there was a statistically P p .01 significant increase in having a DHPS mutation if the duration of sulfa exposure was 11 year (RR, 1.16; ), compared P p .003 with the group of patients who had significant sulfa or sulfone exposure for a duration of !1 year. There was, however, no significant association between choice of sulfa agent (i.e., dapsone vs. TMP/SMX), and P. carinii mutations ( ); mu-P p .15 tations were present in 7 (77%) of the 9 patients receiving TMP/ SMX and in 21 (75%) of the 28 patients receiving dapsone as prophylaxis. Similarly, there was no significant association between dose of dapsone (50 mg/day vs. 100 mg/day; ) P p .22 or TMP/SMX (1 DS/day vs. 1 SS/day; ) and DHPS P p 0.19 mutations. Table 5 shows that the association between sulfa exposure and DHPS mutations was independent of sex (P p ) and race ( ). There were no other statistically sig-. 23 P p .13 nificant differences in age or CD4 counts, HIV viral loads, and prior episodes of PCP with DHPS mutations (table 5) .
Among patients with a DHPS mutation, treatment with a sulfa or sulfone agent failed in 6 (28%) of 21; treatment failure occurred in 3 (21%) of 14 patients receiving TMP/SMX and in 3 (42%) of 7 patients receiving dapsone/trimethoprim (table 6). In contrast, among patients with a WT strain, sulfa or sulfone therapy failed in 3 (7%) of 45, TMP/SMX treatment failed in 1 (4%) of 32, and dapsone/trimethoprim treatment failed in 2 (15%) of 13. Patients with a DHPS mutation had a statistically significant increased risk for failure of sulfa or sulfone therapy (RR, 2.1;
), compared with patients who did not have P p .01 a mutation (table 5) . Patients with a DHPS mutation, however, did not have an increased risk for failure of nonsulfa or nonsulfone agents (RR, 1.003;
), compared with patients P p .1 who did not have a DHPS mutation (table 5) . Each of the 9 treatment failures met the criteria for treatment failure; PAO 2 -PaO 2 measurements were performed for only 2 of the 9 patients. Three of the 6 patients with DHPS mutations in whom sulfa or sulfone treatment failed and who were subsequently switched to a nonsulfa or nonsulfone agent (pentamidine, 2 patients; trimetrexate, 1 patient) had a successful response. Two of the 3 patients with a WT strain in whom sulfa or sulfone treatment failed and who were switched to a nonsulfa or nonsulfone agent (pentamidine, 2 patients) had a successful response.
There was no statistical difference in survival at the completion of therapy between patients who had a DHPS mutation and those who did not ( ); 37 (89%) of 42 patients with P p .21 DHPS mutations survived, compared with 51 (92%) of 55 patients without a mutation. The multivariate model showed that antiretroviral use, increased CD4 cell count, decreased viral load, and prior episode of PCP were not associated with survival ( , .64, .23, and .12, respectively). P p .10
Discussion
This multicenter study of 97 patients from 4 geographically diverse centers reveals P. carinii mutations that are identical to those seen in a previous study. The current study verifies the association between the presence of point mutations and prior sulfa or sulfone prophylaxis first described in 20 AIDS patients Downloaded from https://academic.oup.com/jid/article-abstract/182/2/551/2191531 by guest on 18 December 2018 at Michigan [12] and subsequently noted in follow-up studies conducted at 3 different sites [13] [14] [15] (table 7) . The present study is the first to show that an increased duration of sulfa or sulfone as prophylaxis increases the chance of having a DHPS mutation. It also suggests that the incidence of DHPS mutations may vary considerably by geographic location; it is possible that these differences reflect the variation in choice of chemoprophylactic agents in different medical practice settings. Our study does not find a significant association between dose of sulfa or sulfone agent used and risk of a DHPS mutation.
There are several possible explanations for how duration of sulfa prophylaxis could influence the incidence of mutations. First, prophylactic agents taken by an AIDS patient may select for acquisition of a strain of P. carinii containing mutations transmitted from another individual with pneumonia due to P. carinii with DHPS mutations. The suggestion that PCP results from a recent acquisition of P. carinii rather than a reactivation of a latently acquired infection [16, 17] would be the basis of this interpretation. An alternative explanation for these observations is that an individual patient may harbor genetically diverse strains of P. carinii and that pneumonia caused by a mutant strain may occur selectively in patients who receive sulfa or sulfone as chemoprophylaxis.
The present report shows that, in a minority of patients with DHPS mutations (28%), sulfa or sulfone treatment fails. The failure rate of sulfa or sulfone therapy is, however, higher in patients with PCP with DHPS mutations than in those with a WT strain. The reduction in response rate to sulfa or sulfone agents seen in this report cannot be considered as evidence that DHPS mutations cause sulfa or sulfone resistance. The substantial number of patients treated with dapsone and trimethoprim (6 of 21 patients) may, in fact, have resulted in higher rate of sulfa or sulfone treatment failure, compared with other populations, because dapsone plus trimethoprim may not be as effective as TMP/SMX in the treatment of PCP [18] . In addition, direct proof of sulfa resistance cannot be determined by susceptibility testing using conventional methods, because human P. carinii cannot be grown in culture medium. Thus, additional studies evaluating response rates to sulfa or sulfone agents should be done in different populations of AIDS patients with PCP. Although a previously published study showed that the 3-month survival rate is lower in patients with PCP who had DHPS mutations than in those who had a WT strain [14] , the study did not directly assess response to sulfa or sulfone treatment.
There are several possible explanations for the low sulfa or sulfone treatment failure rates in the presence of a point mutation. One possible explanation is that high concentrations of sulfa or sulfone in pulmonary tissues, achieved with therapeutic doses of dapsone or TMP/SMX, may result in successful treatment of the majority of patients with PCP who harbor DHPS mutations. As with antimicrobial resistance to other organisms, there is not a simple correlation between in vitro measures of resistance and clinical efficacy [19] . For example, most patients with bacterial pneumonia caused by penicillin-resistant Streptococcus pneumoniae nevertheless improve with iv penicillin therapy [20] . The present study also shows that the failure rate for nonsulfa or nonsulfone agents among patients with pneumonia due to P. carinii with DHPS mutations did not differ from the failure rate among those with a WT strain. These findings suggest that P. carinii with DHPS mutations are not more virulent or unlikely to respond to therapy than are WT strains. Finally, our study did not demonstrate the decrease in survival rate of patients with a DHPS mutation that was reported in a recent trial [14] . It is possible that AIDS-associated illnesses other than PCP could have contributed to the survival rates at 3 months in that trial and account for the differences in survival rates reported in our study.
There is reason to suspect that one of the mutations described in this article, thr55rala55, could lead to reduced sulfa or sulfone sensitivity. This amino acid is homologous to thr62 in the Escherichia coli enzyme, which, based on its crystal structure [21] , forms 2 hydrogen bonds with the pterin substrate, one of which will be lost by substitution with alanine. The adjacent amino acid in the P. carinii enzyme is arg56. Its homologue in the E. coli enzyme, arg63, is involved in binding both to the pterin substrate and to sulfa drugs. Thus, the substitution of ala55 for thr55 in the P. carinii enzyme is likely to affect the position of arg56 and its ability to bind to sulfa and sulfone drugs. Indeed, similar mutations in the Plasmodium falciparum DHPS have been found to be associated with sulfa resistance [14] . The other mutation reported here, pro57rser57, also occurs adjacent to arg56 and might similarly affect its binding to substrate and drug. Mutations near this site are responsible for drug resistance in both S. pneumoniae [8] and P. falciparum [9] . Homologues of both mutations have recently been found in sulfa-resistant Mycobacterium leprae [22] . A final reason to suspect that these mutations might be associated with drug resistance is the fact that they are nonsynonymous, which is indicative of positive evolutionary pressure [11] . Amino acid sequence variations have not been demonstrated for P. carinii genes other than DHPS, although DNA sequence variations have been demonstrated in this organism [23] .
The increase in the proportion of specimens with mutations over the study period suggests emergence of mutations due to selective pressure of agents used for prophylaxis; however, we believe that further trials should be done to determine the clinical significance of the DHPS mutations in P. carinii. The significance of DHPS mutations on the selection of secondary prophylaxis, for example, should be evaluated in prospective studies before the assay is used in clinical practice. Furthermore, prospective studies evaluating patients in whom sulfa or sulfa treatment fails should be done before this test can be used to select treatment in clinical practice. Because of the reduced occurrence of PCP in the era of highly active antiretroviral therapy [24] , it is unlikely that such studies may be performed in the near future.
In summary, this multicenter trial confirms the association between sulfa prophylaxis exposure and DHPS mutations and shows that the incidence of mutations is increased by the duration of sulfa prophylaxis. It also illustrates that the majority of patients with pneumonia due to P. carinii with mutations respond to sulfa or sulfone therapy, although the response rate to these agents is lower than the rate among those who have a WT strain. Additional prospective trials using this assay should be done to evaluate the clinical relevance of these findings and to determine the need for the development of new agents for the prophylaxis and therapy of PCP [25] . These studies should be done to determine whether the assay used in the present study could permit physicians to individualize therapy for PCP or to select an agent for secondary prophylaxis after an acute episode has occurred.
